Sanyou Biopharmaceuticals Introduces GEOTA Platform for Drug Research

Jul 10, 2026
Sanyou Biopharmaceuticals has released GEOTA 1.0, a new digital computing platform within its SAI-DA program that simplifies access to AI-driven research tools for drug development.

Sanyou Biopharmaceuticals has introduced GEOTA 1.0, a new digital computing platform designed to support drug research and development, announced in a press release. GEOTA is part of the company's SAI-DA (Sanyou AI-Drug Accelerator) program and serves as an upgrade to its intelligent R&D framework.

According to the company, GEOTA decouples complex AI algorithms into a simplified web interface that allows researchers to access computing functions without coding or bioinformatics expertise. This approach aims to make advanced digital tools more accessible for use in laboratory research and drug discovery.

The first batch of GEOTA's core functions is now open for trial. This release builds on Sanyou's AI-STAL molecular library and its ongoing efforts to improve efficiency and reduce the time required for drug innovation.

We hope you enjoyed this article

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)
Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Market report

2025 Generative AI in Professional Services Report

Thomson Reuters

This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.

Read more

You may also like

Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.